Blood Cancer Journal - Table of Contents alert Volume 4 August 2014

If you are unable to see the message below, click here to view.

Advertisement BD FACSCanto™ has 10-color capability.  Reliable performance, accuracy, and ease of use make the latest BD FACSCanto System a perfect 10 for today's busy clinical labs. Learn how you can achieve dependable outcomes while speeding workflow and reducing training requirements with clinical multi-color flow cytometry systems from BD Biosciences.  bdbiosciences.com/go/canto   TABLE OF CONTENTS Volume 4, August 2014 In this issue Original Articles Letters to the Editor Corrigendum Sign up for e-alerts Web feed Original Articles Top Role of Bruton’s tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells R Bam, S U Venkateshaiah, S Khan, W Ling, S S Randal, X Li, Q Zhang, F van Rhee, B Barlogie, J Epstein and S Yaccoby Blood Cancer J 2014 4: e234; 10.1038/bcj.2014.54 Abstract | Full Text Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis J Lu, J Lu, W Chen, Y Huo, X Huang, J Hou and the Chinese Medical Doctor Association Hematology Branch Blood Cancer J 2014 4: e239; 10.1038/bcj.2014.55 Abstract | Full Text A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia A L Samuels, A H Beesley, B D Yadav, R A Papa, R Sutton, D Anderson, G M Marshall, C H Cole, U R Kees and R B Lock Blood Cancer J 2014 4: e232; 10.1038/bcj.2014.52 Abstract | Full Text A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia J F Seymour, D W Kim, E Rubin, A Haregewoin, J Clark, P Watson, T Hughes, I Dufva, J L Jimenez, F-X Mahon, P Rousselot, J Cortes, G Martinelli, C Papayannidis, A Nagler and F J Giles Blood Cancer J 2014 4: e238; 10.1038/bcj.2014.60 Abstract | Full Text Depletion of STAT5 blocks TEL–SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice C Sprissler, D Belenki, H Maurer, K Aumann, D Pfeifer, C Klein, T A Müller, S Kissel, J Hülsdünker, J Alexandrovski, T Brummer, H Jumaa, J Duyster and C Dierks Blood Cancer J 2014 4: e240; 10.1038/bcj.2014.53 Abstract | Full Text Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment H Sugihara, D Chihara, K Seike, K Fukumoto, M Fujisawaa, Y Suehara, Y Nishida, M Takeuchi and K Matsue Blood Cancer J 2014 4: e235; 10.1038/bcj.2014.56 Abstract | Full Text Letters to the Editor Top Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia K D Cummins, S M Jane, S Nikovic, A Bazargan, R Filshie, G Sutrave, M Hertzberg, A Scott, S Lane, C K Yannakou, D Ritchie, J D'Rozario, J Black, K Bavishi and A Wei Blood Cancer J 2014 4: e237; 10.1038/bcj.2014.59 Full Text High DNA-methyltransferase 3B expression predicts poor outcome in acute myeloid leukemia, especially among patients with co-occurring NPM1 and FLT3 mutations D Monteferrario, S M Noordermeer, S Bergevoet, G Huls, J H Jansen and B A van der Reijden Blood Cancer J 2014 4: e233; 10.1038/bcj.2014.51 Full Text KIT mutations in primary mediastinal B-cell lymphoma P D Nagel, A Stenzinger, F M Feld, M D Herrmann, S Brüderlein, T F E Barth, R Marienfeld, V Endris, W Weichert, K-M Debatin, M-A Westhoff, D Lessel, P Möller and J K Lennerz Blood Cancer J 2014 4: e241; 10.1038/bcj.2014.61 Full Text Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression Y Oki, D Buglio, J Zhang, Y Ying, S Zhou, A Sureda, D Ben-Yehuda, P L Zinzani, H M Prince, S J Harrison, M Kirschbaum, P B Johnston, A Shen, B von Tresckow and A Younes Blood Cancer J 2014 4: e236; 10.1038/bcj.2014.58 Full Text Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q) M A Sekeres, A S Swern, P Fenaux, P L Greenberg, G F Sanz, J M Bennett, F Dreyfus, A F List, J S Li and M M Sugrue Blood Cancer J 2014 4: e242; 10.1038/bcj.2014.62 Full Text Corrigendum Top The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma E Derenzini, M Lemoine, D Buglio, H Katayama, Y Ji, R E Davis, S Sen and A Younes Blood Cancer J 2014 4: e231; 10.1038/bcj.2014.57 Full Text You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.